FDA has reviewed the final results from the post-approval study conducted by SynCardia Systems, LLC. for their Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System (C2 Driver System). These final results indicate a higher mortality rate and higher stroke rate for patients initially supported with the C2 Driver System compared to patients initially supported with the previous generation driver, the Circulatory Support System (CSS) Console.
Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers – Risk of Mortality and Stroke
More from FDA News AlertsMore posts in FDA News Alerts »
- Federal Judge Enters Consent Decree with Utah-based Dietary Supplement Manufacturer
- Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines
- FDA In Brief: FDA Announces Investigation of Salmonella Outbreak Linked to Whole, Fresh Onions
- Merck Issues Voluntary Nationwide Recall of CUBICIN® (Daptomycin for Injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles
- FDA Issues Landmark Proposal to Improve Access to Hearing Aid Technology for Millions of Americans